PA
MANH icon

PharVision Advisers’s Manhattan Associates MANH Stock Holding History

PharVision Advisers’s Portfolio MANH Stock Details MANH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,863
Closed -$382K – 876
2025
Q3 		$382K Buy
+1,863
New +$394K 0.21% 97

Other funds holding MANH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

PharVision Advisers's MANH Position: Q4 2025 in Review

PharVision Advisers sold out of Manhattan Associates (MANH) in Q4 2025, closing a stake of 1,863 shares — an estimated $382K sold.

PharVision Advisers first reported a position in MANH in Q3 2025 and held it in 1 quarter. The position peaked at $382K in Q3 2025. 579 funds tracked by Wall St. Rank hold MANH as of Q4 2025.

  • PharVision Advisers reported no remaining Manhattan Associates position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 1,863 Manhattan Associates shares in Q4 2025, an estimated $382K.
  • PharVision Advisers first reported a position in Manhattan Associates in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Manhattan Associates position peaked at $382K in Q3 2025.
  • 579 funds tracked by Wall St. Rank held Manhattan Associates as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.